P1, N=21, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

The patient initially received nab-paclitaxel plus gemcitabine, achieving tumor shrinkage. Upon tumor regrowth, she was treated with the anti-programmed cell death-1 immune checkpoint inhibitor (ICI) pembrolizumab, which resulted in significant tumor reduction. This is the first case report of MCP with dMMR/MSI-H due to MLH1 promoter hypermethylation, effectively treated with an ICI.

P1/2, N=104, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting

P1, N=70, Recruiting, Shandong Boan Biotechnology Co., Ltd

P2/3, N=10, Not yet recruiting, University Health Network, Toronto | Trial completion date: Mar 2031 --> Jun 2031 | Initiation date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2031 --> Jun 2031

Moreover, in vivo evaluation on KYSE-150 tumor-bearing mice models also demonstrated the supplementation of LNT-SeNPs with low dosage during the Nab-PTX treatment may synergize the antitumor efficacy and significantly mitigate the adverse reactions or toxicity resulting from a substantial dose of Nab-PTX. Overall, along with the facile accessibility of raw materials, this study reports LNT-SeNPs as a synergistic agent to promote the antitumor efficacy of Nab-PTX, which may be translated as a wide-applicable, efficient and highly safe strategy for clinical treatment of ESCC.

A total of 126 patients with advanced PLC were divided into two treatment groups: the nab-PTX/OXA group (n=66) and the sorafenib (Sor)/OXA group (n=60), with a treatment cycle of 21 days. In short, PTX combined with OXA demonstrated favorable efficacy in treating advanced PLC. This regimen not only improved SQ and QoL but also prolonged survival.

P=N/A, N=276, Completed, Kochi University

P1, N=120, Recruiting, Tianjin ConjuStar Biologics Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=253, Recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2028 --> Sep 2026

BETINA study demonstrated promising efficacy and favorable tolerance in treating patients with mTNBC with bevacizumab with tislelizumab and nab-paclitaxel.

P1, N=100, Recruiting, Tianjin ConjuStar Biologics Co., Ltd. | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Jun 2025 --> Mar 2026

P1/2, N=57, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting

P=N/A, N=200, Completed, The Second Affiliated Hospital of Shandong First Medical University; The Second Affiliated Hospital of Shandong First Medical University

P=N/A, N=394, Completed, Shenzhen Second People's Hospital; Shenzhen Second People's Hospital

P=N/A, N=80, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital, Sichuan University

P4, N=60, Not yet recruiting, Ordos Central Hospital; Ordos Central Hospital

P1/2, N=61, Not yet recruiting, Washington University School of Medicine

GC plus immunotherapy is still the standard of care for late stage BTC. PD-L1 expression and TMB were not good predictors for selecting patients who would benefit more from immunotherapy plus chemotherapy.

P1/2, N=57, Recruiting, Northwestern University | Trial primary completion date: Sep 2024 --> Jun 2025

P2, N=30, Recruiting, Barbara Ann Karmanos Cancer Institute | Not yet recruiting --> Recruiting

PDO-based NAC shows a promising resectable rate in BRPC patients, with good tolerance. Potential drug-resistant and sensitive genes and cell-cell interaction changes may participate in the development of gemcitabine resistance.

In a CD44+ tumor model, PTX-loaded Ac-HSA-PLA NPs outperformed Abraxane®, achieving complete tumor elimination without recurrence, two months post-treatment, while Abraxane treated tumors continued to grow (tumor volume increased five fold). The Ac-HSA-PLA (PTX) NPs also demonstrated minimal systemic toxicity, suggesting that Ac-HSA could be a promising alternative for targeted cancer therapy in CD44-expressing cancers.

P=N/A, N=110, Active, not recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Trial completion date: Jan 2025 --> Apr 2025

P3, N=512, Recruiting, Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2025 --> Dec 2026

Drawing from clinical examples, including the success of albumin-bound paclitaxel (Abraxane) and new formulations like Pazenir and Fyarro (for Sirolimus), we identify gaps in current knowledge and propose strategies to optimize albumin-based systems. In conclusion, albumin-based nanoparticles, when tailored with appropriate modifications, have the potential to bypass multidrug resistance and improve the targeting of cancer cells. By enhancing albumin's ability to efficiently deliver therapeutic agents, these carriers represent a promising approach to addressing one of oncology's most persistent challenges, with substantial potential to improve cancer treatment outcomes.

P1/2, N=40, Recruiting, Mayo Clinic | Trial primary completion date: Mar 2025 --> Mar 2026

P1, N=36, Terminated, Dana-Farber Cancer Institute | Phase classification: P1/2 --> P1 | Completed --> Terminated; Phase II was not pursued due to futility based on the results of the NAPOLI-3 therapeutic clinical trial.

P1, N=21, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jan 2026

The incidence of adverse reactions was 33.33% (15/45), which was slightly higher than that of 28.89% (13/45) in the control group, the difference was not statistically significant (P>0.05). Albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide is a safe regimen that can further enhance the effect of neoadjuvant chemotherapy in the treatment of breast cancer, and it has a certain value for dissemination in the treatment of breast cancer can further enhance the effect of neoadjuvant chemotherapy in patients, which is of certain value for clinical promotion.

Patients with lung-only mPDAC demonstrate an improved prognosis relative to those with liver-only mPDAC. Responses to chemotherapy do not explain these differences. Organotropic metastatic tumor diversity is mirrored at the molecular level in PDAC.

P1, N=36, Enrolling by invitation, Hangzhou Adcoris Biopharmacy Co., Ltd | Trial completion date: Jul 2024 --> Jul 2025

P=N/A, N=536, Enrolling by invitation, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P2, N=67, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Dec 2025

Consistently, the combination of nab-PTX with an AMPK inhibitor exhibits a greater therapeutic efficacy in LKB1-WT NSCLC using xenograft models in vivo. Taken together, our data reveal a novel role of LKB1-AMPK-SLC7A11-GSH signaling pathway in the primary resistance to nab-PTX, and provide a therapeutic strategy for the treatment of LKB1-WT NSCLC by targeting the LKB1-AMPK-SLC7A11-GSH pathway.

P1/2, N=30, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | N=237 --> 30 | Trial completion date: Feb 2030 --> Oct 2027 | Trial primary completion date: Feb 2030 --> Aug 2027

P2, N=336, Completed, West German Study Group | Active, not recruiting --> Completed

Pre-treatment EQ-5D-5L utility value, along with albumin and CEA, was an independent efficacy predictor and prognostic factor in patients with UPC treated with first-line GnP. Their usefulness should be validated in future studies.

To investigate the effect of BRCA1 and/or BRCA2 tumor pathogenic variants (tPVs) by comparing 2 deescalated neoadjuvant regimens (nab-paclitaxel plus either carboplatin or gemcitabine) on pathologic complete response (pCR), invasive disease-free survival (IDFS), and overall survival (OS) of patients with early-stage triple-negative breast cancer (TNBC). These findings suggest that BRCA1 and/or BRCA2 tPV status could be a candidate marker for a deescalation strategy in early-stage TNBC; however, prospective validation of survival outcomes in larger cohorts with differentiation between germline and somatic pathogenic variants is necessary. ClinicalTrials.gov Identifier: NCT01815242.

Nab-paclitaxel significantly upregulated phosphorylated AMPKα, apoptotic proteins as zinc finger matrin-type 3, and nuclear factor kappa-B levels following radiation exposure. Our study confirmed the radiosensitizing effect of nab-paclitaxel on cholangiocarcinoma cells through a dual effect of antitumor proliferation and inhibition of M2 macrophage polarization, and the underlying mechanism involved activation of the AMPK signaling pathway.

P=N/A, N=32, Completed, Translational Drug Development | Active, not recruiting --> Completed

The findings confirmed the activation of acidic/neutral autophagosomes in acridine orange/ethidium bromide (AO/EB) and nuclear fragmentation was clearly shown by 4', 6-diamidino-2 phenylindole (DAPI) nuclear stains. The findings provide the basis for the potential application of arabinoxylans as a great vehicle for the encapsulation of chemotherapeutic agents such as PTX for target delivery, and also as an immune mediator.